SG173997A1 - Human endogenous retrovirus polypeptide compositions and methods of use thereof - Google Patents

Human endogenous retrovirus polypeptide compositions and methods of use thereof Download PDF

Info

Publication number
SG173997A1
SG173997A1 SG2011052784A SG2011052784A SG173997A1 SG 173997 A1 SG173997 A1 SG 173997A1 SG 2011052784 A SG2011052784 A SG 2011052784A SG 2011052784 A SG2011052784 A SG 2011052784A SG 173997 A1 SG173997 A1 SG 173997A1
Authority
SG
Singapore
Prior art keywords
herv
polypeptide
cells
leu
cell
Prior art date
Application number
SG2011052784A
Other languages
English (en)
Inventor
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Mario Ostrowski
R Bradley Jones
Ashish Agrawal
Jack Lenz
Seth Rakoff-Nahoum
Frederick M Hecht
Original Assignee
Univ California
David Gladstone Inst
Einstein Coll Med
Mario Ostrowski
R Bradley Jones
Rakoff Nahoum Seth Ferguson Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, David Gladstone Inst, Einstein Coll Med, Mario Ostrowski, R Bradley Jones, Rakoff Nahoum Seth Ferguson Singapore Pte Ltd filed Critical Univ California
Publication of SG173997A1 publication Critical patent/SG173997A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2011052784A 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof SG173997A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21

Publications (1)

Publication Number Publication Date
SG173997A1 true SG173997A1 (en) 2011-09-29

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011052784A SG173997A1 (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Country Status (15)

Country Link
US (2) US20080171061A1 (enExample)
EP (1) EP2046380A4 (enExample)
JP (1) JP2009544614A (enExample)
KR (1) KR20090060410A (enExample)
CN (1) CN101557823A (enExample)
AU (1) AU2007275693A1 (enExample)
BR (1) BRPI0714714A2 (enExample)
CA (1) CA2658393A1 (enExample)
IL (1) IL196516A0 (enExample)
MX (1) MX2009000659A (enExample)
NO (1) NO20090818L (enExample)
RU (1) RU2009106089A (enExample)
SG (1) SG173997A1 (enExample)
WO (1) WO2008011120A2 (enExample)
ZA (1) ZA200900379B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2878307T3 (pl) 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
JP5504163B2 (ja) * 2008-09-18 2014-05-28 学校法人慶應義塾 がんの診断方法と治療方法
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
EP4502609A3 (en) 2012-01-26 2025-04-09 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP2970985A1 (en) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
DK3478711T3 (da) * 2016-06-30 2022-12-12 Us Health Herv-e-reaktive t-cellereceptorer og fremgangsmåder til anvendelse
JP2019528071A (ja) * 2016-08-23 2019-10-10 エイムヴィオン・アクティエセルスカブAimVion A/S 新規免疫刺激ペプチド
CA3049244A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
JP7457642B2 (ja) * 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
JP7277466B2 (ja) 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および/または治療における使用のためのワクチン
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
US20210330774A1 (en) * 2018-09-06 2021-10-28 Centre Leon Berard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
US20240189247A1 (en) * 2022-11-16 2024-06-13 The General Hospital Corporation Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
EP1425299A2 (en) * 2001-09-06 2004-06-09 NovImmune S.A. Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
EP1521594B1 (en) * 2001-12-07 2013-10-02 Novartis Vaccines and Diagnostics, Inc. Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
EP2516459A1 (en) * 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
EP2046380A2 (en) 2009-04-15
RU2009106089A (ru) 2010-08-27
IL196516A0 (en) 2011-08-01
CN101557823A (zh) 2009-10-14
BRPI0714714A2 (pt) 2013-04-09
EP2046380A4 (en) 2013-05-01
MX2009000659A (es) 2009-06-08
US20080171061A1 (en) 2008-07-17
US20130323279A1 (en) 2013-12-05
ZA200900379B (en) 2010-08-25
WO2008011120A3 (en) 2008-11-06
KR20090060410A (ko) 2009-06-12
AU2007275693A1 (en) 2008-01-24
NO20090818L (no) 2009-04-17
CA2658393A1 (en) 2008-01-24
JP2009544614A (ja) 2009-12-17
WO2008011120A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
SG173997A1 (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
US20110046042A1 (en) Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof
SK12402001A3 (sk) Peptidy HIV, antigény, zloženie vakcín, súprava na imunologickú skúšku a spôsob detekcie protilátok vyvolaných HIV
US11660335B2 (en) Vaccines against coronavirus and methods of use
US8043623B2 (en) Immunogenic peptides for the treatment of prostate and breast cancer
EP1309860B1 (fr) Procede de criblage de peptides utilisables en immunotherapie
JP2015500854A (ja) エンベロープウイルスにより引き起こされる疾病を治療するための方法および組成物
IT202000009688A1 (it) Proteine di fusione di ancoraggio a esosomi
US9572873B2 (en) Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
US20150174239A1 (en) Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine
US20230310585A1 (en) Vaccine for viral pathogens
WO2014022475A2 (en) Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
US20220370598A1 (en) Vaccines Against Coronavirus and Methods of Use
EP0835309B1 (fr) Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv
WO2005005465A2 (en) Methods and compositions to enhance immune responses via recall antigens
HK1135023A (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
US20080267989A1 (en) Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens
Berzofsky Human Immunodeficiency Virus: Structural Features of T-Cell
WO2022125610A1 (en) Perforin inhibitors and uses thereof
Maksaereekul et al. Cloning and Sequencing of Feline CD107a
US20060122368A1 (en) Antigen delivery platform